Usefulness of chemotherapy beyond the second line for metastatic breast cancer: A therapeutic challenge

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 1, 2010, Pages 113-120

  Vauléon, Elodie ^a,b   Mesbah, Habiba ^a   Laguerre, Brigitte ^a   Gédouin, Daniel ^a   Lefeuvre Plesse, Claudia ^a   Levêque, Jean ^a,b   Audrain, Odile ^a   Kerbrat, Pierre ^a,b  

^a Eugène Marquis   (France)

^b European University in Brittany   (France)

Author keywords

Breast cancer; Chemotherapy; Prognosis factor; Third line; Treatment outcome

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FLUOROURACIL; GEMCITABINE; VINCA ALKALOID; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; BREAST TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RETREATMENT; RISK FACTOR; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; RETREATMENT; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77951926427     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1141-3     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: Globocan 2000. Int J Cancer 94:153-156
2. Parkin DM (2001) Global cancer statistics in the year 2000. Lancet Oncol 2:533-543
3. Kerbrat P, Botton E (2007) Soins palliatifs: peut-on parler de qualité de vie en phase métastatique? In: Serin D, de Rauglaudre G (eds) Cancer du sein avancé: 29es Journées de la Société Française de Sénologie et Pathologie Mammaire (SFSPM) Avignon, 14-16 novembre 2007, Paris, pp 181-189
4. Tacca O, LeHeurteur M, Durando X et al (2009) Metastatic breast cancer: overall survival related to successive chemotherapies. What do we gain after the third line? Cancer Invest 27:81-85
5. Bergh J, Jonsson PE, Glimelius B et al (2001) A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 40:253-281 (Pubitemid 32590835)
6. Carrick S, Parker S, Wilcken N et al (2005) Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev: CD003372
7. Anonymous (2007) Recommandations pour la pratique clinique: cancers du Sein, Saint-Paul de Vence 2007. http://cours-saintpaul.fr/10/recommandations. html
8. A'Hern RP, Smith IE, Ebbs SR (1993) Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805
9. Pivot X, Asmar L, Buzdar AU et al (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82:529-534
10. Crown J, O'Leary M, Ooi WS (2004) Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience. Oncologist 9(Suppl 2):24-32
11. Nabholtz JM, Falkson C, Campos D et al (2003) Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 21:968-975
12. Porkka K, Blomqvist C, Rissanen P et al (1994) Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer. J Clin Oncol 12:1639-1647
13. Perez EA, Vogel CL, Irwin DH et al (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223
14. Atalay G, Biganzoli L, Renard F et al (2003) Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39:2439-2449
15. Al-Batran SE, Bischoff J, von Minckwitz MG et al (2006) The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial. Br J Cancer 94:1615-1620
16. Pierga JY, Robain M, Jouve M et al (2001) Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients. Ann Oncol 12:231-237
17. Pierga JY, Asselain B, Jouve M et al (2001) Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer 91:1079-1089
18. Insa A, Lluch A, Prosper F et al (1999) Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients. Breast Cancer Res Treat 56:67-78
19. Yamamoto N, Watanabe T, Katsumata N et al (1998) Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol 16:2401-2408
20. Ahmann FR, Jones SE, Moon TE (1988) The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer. J Surg Oncol 37:116-122
21. Greenberg PA, Hortobagyi GN, Smith TL et al (1996) Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205
22. Gennari A, Conte P, Rosso R et al (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104:1742-1750
23. Conte PF, Guarneri V, Bruzzi P et al (2004) Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial. Cancer 101:704-712
24. Miles D, von Minckwitz MG, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13-19
25. McQuellon RP, Muss HB, Hoffman SL et al (1995) Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 13:858-868
26. Slevin ML, Plant H, Lynch D et al (1988) Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109-112
27. Keller AM, Mennel RG, Georgoulias VA et al (2004) Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxanerefractory advanced breast cancer. J Clin Oncol 22:3893-3901
28. Jones S, Winer E, Vogel C et al (1995) Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer. J Clin Oncol 13:2567-2574
29. O'Shaughnessy JA, Blum J, Moiseyenko V et al (2001) Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 12:1247-1254
30. Coates AS, Hurny C, Peterson HF et al (2000) Quality-of-life scores predict outcome in metastatic but not early breast cancer. International Breast Cancer Study Group. J Clin Oncol 18:3768-3774
31. Geels P, Eisenhauer E, Bezjak A et al (2000) Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 18:2395-2405
32. McLachlan SA, Pintilie M, Tannock IF (1999) Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost. Breast Cancer Res Treat 54:213-223
33. Carlson RW (1998) Quality of life issues in the treatment of metastatic breast cancer. pp. 27-31
34. Waldron D, O'Boyle CA, Kearney M et al (1999) Quality-of-life measurement in advanced cancer: assessing the individual. J Clin Oncol 17:3603-3611
35. Rouzier R, Wagner P, Morandi P et al (2005) Gene expression profiling of primary breast cancer. Curr Oncol Rep 7:38-44
36. Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11:5678-5685